GMG
Clinical trials for GMG explained in plain language.
Never miss a new study
Get alerted when new GMG trials appear
Sign up with your email to follow new studies for GMG, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested for Long-Term safety in kids with rare muscle disease
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of efgartigimod in children with generalized myasthenia gravis, a disease that causes muscle weakness. The 12 participants are kids who already took part in earlier studies of this drug. They will continue to receive efgartigimod either th…
Matched conditions: GMG
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising drug trial for kids with rare Muscle-Weakening disease
Disease control OngoingThis study tests a drug called ravulizumab in 12 children aged 6 to 18 with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The goal is to see how the drug works in the body and if it helps control symptoms. Participants receive the drug through an I…
Matched conditions: GMG
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Hope for rare Muscle-Weakening disease: new drug trial targets Antibody-Negative patients
Disease control OngoingThis study tests an investigational drug called efgartigimod, given intravenously, for adults with generalized myasthenia gravis (gMG) who do not have the typical acetylcholine receptor antibodies. The trial compares the drug to a placebo to see if it improves daily activities an…
Matched conditions: GMG
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC